Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 0.77 |
| ▸ | FNTB | P49356 | 13/20 | 0.77 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609148 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL30508947 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL169443 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL25386448 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL812431 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL23674223 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL18042467 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL1379703 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL2506806 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL29420213 | 1.00 | FNTA (0.77) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116823728-B | Meibomian gland segmentation method based on image processing | 苏州大学 | 2024-08-16 | — | — | CN | claimed |
| CN-116823728-A | Meibomian gland segmentation method based on image processing | 苏州大学 | 2023-09-29 | — | — | CN | claimed |
| US-20200299735-A1 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-09-24 | — | — | US | claimed |
| WO-2018144996-A1 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | Manus Bio, Inc. (US) | 2018-08-09 | — | — | WO | claimed |
| JP-4579415-B2 | — | — | 2010-11-10 | — | — | JP | claimed |
| EP-1088333-A4 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | claimed |
| EP-0733709-B1 | Mutated farnesyldiphosphate synthase capable of synthesizing geranylgeranyldiphosphate and gene coding therefor | TOYOTA MOTOR CO LTD (JP) | 2005-05-11 | — | — | EP | claimed |
| US-6699850-B2 | ORAL FORMULATION OF A COMBINATION OF NITROGEN-CONTAINING BISPHOSPHONATE OR ITS SALT AND AN ISOPRENOID COMPOUND FOR INHIBITING BONE RESOPRTION IN A MAMMAL WHILE COUNTERACTING THE OCCURRENCE OF ADVERSE GASTROINTESTINAL EFFECT | MERCK & CO., INC. | 2004-03-02 | — | — | US | claimed |
| US-20030125573-A1 | Method of vitamin production | DCV, INC., D/B/A BIO-TECHNICAL RESOURCES | 2003-07-03 | — | — | US | claimed |
| EP-1089731-A4 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO INC (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1095002-A1 | METHOD OF VITAMIN PRODUCTION | DCV Inc. doing business as Bio-Technical Resourses (US) | 2001-05-02 | — | — | EP | claimed |
| EP-1089731-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| EP-1088333-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067809-A9 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO INC (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2000001649-A1 | METHOD OF VITAMIN PRODUCTION | DCV, INC. DOING BUSINESS AS BIO-TECHNICAL RESOURCES (US) | 2000-01-13 | — | — | WO | claimed |
| WO-2000001650-A1 | METHOD OF VITAMIN PRODUCTION | DCV, INC. DOING BUSINESS AS BIO-TECHNICAL RESOURCES (US) | 2000-01-13 | — | — | WO | claimed |
| WO-1999066929-A1 | COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| WO-1999067809-A1 | COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORPTION | MERCK & CO., INC. (US) | 1999-12-29 | — | — | WO | claimed |
| EP-0779298-B1 | Thermostable geranylgeranyl diphosphate synthase | TOYOTA MOTOR CO LTD (JP) | 1999-06-23 | — | — | EP | claimed |
| EP-0779298-A2 | Thermostable geranylgeranyl diphosphate synthase | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 1997-06-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125573-A1 | Method of vitamin production | TTPA, FNTA, GGPS1 | FNTA 2/4885FNTB 10/4885PGGT1B 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.